Literature DB >> 29235871

Increased Levels of Circulating Fatty Acids Are Associated with Protective Effects against Future Cardiovascular Events in Nondiabetics.

Muhammad Anas Kamleh1, Olga McLeod2, Antonio Checa1, Damiano Baldassarre3,4, Fabrizio Veglia4, Karl Gertow2, Steve E Humphries5, Rainer Rauramaa6, Ulf de Faire7,8, Andries J Smit9, Philippe Giral10, Sudhir Kurl11, Elmo Mannarino12, Elena Tremoli3,4, Angela Silveira2, John Örvik2, Anders Hamsten2, Craig E Wheelock1.   

Abstract

Cardiovascular disease (CVD) is a major cause of morbidity and mortality worldwide, particularly in individuals with diabetes. The current study objective was to determine the circulating metabolite profiles associated with the risk of future cardiovascular events, with emphasis on diabetes status. Nontargeted metabolomics analysis was performed by LC-HRMS in combination with targeted quantification of eicosanoids and endocannabinoids. Plasma from 375 individuals from the IMPROVE pan-European cohort was included in a case-control study design. Following data processing, the three metabolite data sets were concatenated to produce a single data set of 267 identified metabolites. Factor analysis identified six factors that described 26.6% of the variability in the given set of predictors. An association with cardiovascular events was only observed for one factor following adjustment (p = 0.026). From this factor, we identified a free fatty acid signature (n = 10 lipids, including saturated, monounsaturated, and polyunsaturated fatty acids) that was associated with lower risk of future cardiovascular events in nondiabetics only (OR = 0.65, 0.27-0.80 95% CI, p = 0.030), whereas no association was observed among diabetic individuals. These observations support the hypothesis that increased levels of circulating omega-6 and omega-3 fatty acids are associated with protective effects against future cardiovascular events. However, these effects were only observed in the nondiabetic population, further highlighting the need for patient stratification in clinical investigations.

Entities:  

Keywords:  cardiovascular disease; diabetes; eicosanoids; endocannabinoids; fatty acids; metabolomics

Mesh:

Substances:

Year:  2018        PMID: 29235871     DOI: 10.1021/acs.jproteome.7b00671

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  3 in total

1.  Regulatory T cells use arginase 2 to enhance their metabolic fitness in tissues.

Authors:  Margaret M Lowe; Ian Boothby; Sean Clancy; Richard S Ahn; Wilson Liao; David N Nguyen; Kathrin Schumann; Alexander Marson; Kelly M Mahuron; Gillian A Kingsbury; Zheng Liu; Priscila Munoz Sandoval; Robert Sanchez Rodriguez; Mariela L Pauli; Keyon Taravati; Sarah T Arron; Isaac M Neuhaus; Hobart W Harris; Esther A Kim; Uk Sok Shin; Matthew F Krummel; Adil Daud; Tiffany C Scharschmidt; Michael D Rosenblum
Journal:  JCI Insight       Date:  2019-12-19

2.  Race-based and sex-based differences in bioactive lipid mediators after myocardial infarction.

Authors:  Ganesh V Halade; Vasundhara Kain; Chrisly Dillion; Mark Beasley; Tanja Dudenbostel; Suzanne Oparil; Nita A Limdi
Journal:  ESC Heart Fail       Date:  2020-05-04

Review 3.  Methods of the Analysis of Oxylipins in Biological Samples.

Authors:  Ivan Liakh; Alicja Pakiet; Tomasz Sledzinski; Adriana Mika
Journal:  Molecules       Date:  2020-01-15       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.